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Type 2 diabetes mellitus (T2DM) and cardiovascular dis-
ease (CVD) are leading and closely interlinked global
health challenges.1 The burdens of T2DM and CVD are es-
pecially high in South Asia, one of the most populous and
the most densely populated regions of the world.2,3 The
prevalence of diabetes in South Asia has risen more rapidly
than in other large geographical regions,4 and it is pro-
jected that South Asia will account for 40% of the global
CVD burden by 2020.5 In addition, T2DM and CVD de-
velop at an earlier age in South Asians than in their
European counterparts6,7.
Identification of the primary risk factors for T2DM and
CVD is central to the development of effective approaches
for the prevention and treatment of chronic diseases such
as T2DM and CVD.8 However, epidemiological data are
currently sparse for South Asia, with evidence on the driv-
ers of T2DM and CVD being predominantly based on
cross-sectional studies that recorded a narrow range of
exposures and without longitudinal assessments.3,5,6,9 The
few available prospective studies are largely derived from
investigations of South Asians residing in Western coun-
tries, and are further limited by small sample size and in-
complete phenotypic characterization.3 To better
understand the wide range of exposures that contribute to
the development of T2DM and CVD in South Asians, a
large-scale population-based study that collects informa-
tion on demographic, lifestyle, clinical, environmental and
genomic variables is needed.
To address this important need, we have established a
unique cross-sectional population-based study focused on
the South Asian population: the South Asia Biobank
(SAB). SAB was launched in 2018 as a partnership between
collaborating centres in Bangladesh, India, Pakistan, Sri
Lanka and the UK.10 SAB includes rich demographic, life-
style, clinical, environmental and phenotypic data and bio-
logical samples from more than 50 000 South Asian
participants. This resource will enable a broad range of ep-
idemiological research, including the development of pre-
vention and treatment approaches, discovery of novel
molecular biomarkers, risk stratification algorithms and
innovative therapeutic approaches for better prevention of
T2DM and CVD in South Asians. The specific initial
objectives of SAB are as follows.
i. Establish a network of non-communicable disease
(NCD) surveillance sites in Bangladesh, India, Pakistan
and Sri Lanka, using common protocols and plat-
forms, in partnership with regional centres of excel-
lence in South Asia.
ii. Complete structured health assessments on a represen-
tative sample of at least 50 000 South Asians aged
18 years and above, residing at all surveillance sites.
iii. Use the data to identify the genetic and environmental
factors underlying non-communicable diseases in
South Asians, and translate the findings into new
approaches for maintenance of health and well-being.
The South Asia Biobank is conducted in accordance
with the recommendations for physicians involved in re-
search on human subjects, adopted by the 18th World
Medical Assembly, Helsinki, 1964, and later revisions.
Research approval was obtained from the Imperial College
London Research Ethics Committee (reference: 18IC4698)
and local institutional review boards in each of the partici-
pating countries.
Data collected
SAB is a cross-sectional population-based study that
recruited participants from 118 surveillance sites that were
centred on local primary community health care units in
five study regions: Bangladesh, South India, North India,
Pakistan and Sri Lanka. The locations of all surveillance
sites are demonstrated in Figure 1. Recruitment started in
November 2018 and ended in March 2020 (due to the pan-
demic of COVID-19).
We recruited men and women of self-reported South
Asian ethnicity and aged 18 years and above. We ex-
cluded women who were currently pregnant, as well as
people who were not permanent residents of the surveil-
lance site (residence for 12 months or more required).
Key features
• The South Asia Biobank (SAB) is the first
comprehensive biobank of South Asian individuals,
established to identify the risk factors and their
complex interactions underlying the development of
type-2 diabetes mellitus (T2DM), cardiovascular
disease (CVD) and other chronic diseases in South
Asians.
• SAB is a cross-sectional investigation in Bangladesh,
India, Pakistan and Sri Lanka, starting in November
2018 and ending in March 2020.
• A total of 52 853 participants took part in SAB, and
demographic, lifestyle, clinical, environmental and
phenotypic data and biological samples are
available.
• Interested research collaborators could refer to the
SAB website [https://www.ghru-southasia.org/] or
contact Professor John C Chambers [john.
chambers@imperial.ac.uk].
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We also excluded people with serious illness expected to
reduce life expectancy to less than 12 months, those
who planned to leave the surveillance site within the
next 12 months and those unable or unwilling to give in-
formed consent.
The surveillance sites at which recruitment occurred in
each study region are summarized in Supplementary Table
S1 (available as Supplementary data at IJE online).
Governmental census data and available household listings
were used, together with house-to-house visits by research
teams and local primary care workers, to identify (enumer-
ate) the resident population. All individuals in each house-
hold who met the inclusion criteria were invited to take
part, and their demographic details were obtained in
their households. We worked closely with senior com-
munity members (e.g. teachers, employers, religious
leaders) to support and facilitate engagement in the
study. Explanations of the project’s purpose were pro-
vided in writing and using videos, in relevant South
Asian languages, supported by bilingual translators.
By March 2020 we recruited a total of 52 853 subjects:
13 954 from Bangladesh, 8620 from South India, 9469
from North India, 5875 from Pakistan and 14 935 from
Sri Lanka. The response rate based on enumerated popula-
tion in each surveillance site ranged from 17.6% in North
India to 72.3 % in Pakistan (see Supplementary Table S2
for more details, available as Supplementary data at IJE
online). The demographic structure of the study partici-
pants and the comparison with the National Population
data in 2015, obtained from the United Nations
Population Division, are shown in Table 1.11
Measures
Participants were invited to attend the survey sites between
7 am and 11 am in the fasting state (water only after mid-
night). Structured assessments of participants were con-
ducted in six complementary domains: (i) Registration and
consent; (ii) Health and lifestyle questionnaire; (iii).
Physical measurements; (iv) Biological samples (blood and
Figure 1. Locations of South Asia Biobank (SAB) surveillance sites
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spot urine); (v) Physical activity monitoring; and (vi) 24-h
dietary recall. Procedures and training were standardized
between countries and surveillance sites.
Registration and consent
Written, informed consent was obtained from all partici-
pants for data collection and inclusion in the research.
Informed consent included permission for the data and
samples collected to be used for chronic disease research,
including data sharing with national and international
bodies concerned with prevention and control of T2DM
and CVD and for molecular epidemiological research.
Consent was facilitated using videos (available in major
South Asian languages). A unique study identity number
(ID) was allocated to each participant.
Questionnaire
An interviewer-administered health and lifestyle question-
naire was used to collect information on behavioural risk
factors (smoking, alcohol use, physical activity and con-
sumption of fruits/vegetables), personal and family medical
history, medications and socioeconomic status. The ques-
tionnaire was founded on the extended World Health
Organization (WHO) STEPwise approach to surveillance
questionnaire that is widely used in global disease surveil-
lance and which was adapted for use in the South Asia con-
text, through incorporating additional questions.12
Physical measurements
These included: (i) anthropometry (height, weight, waist
and hip circumference and bio-impedance for body fat
composition); (ii) blood pressure by digital device; (iii) car-
diac evaluation by 12-lead electrocardiogram to identify
arrhythmia, left ventricular hypertrophy and previous
myocardial infarction; (iv) retinal photography for
assessment of retinal disease, including hypertensive and
diabetic retinopathy; and (v) respiratory evaluation by spi-
rometry to assess for smoking/environment-related lung
injury.
Biological samples
Using venesection by trained phlebotomists, 25 ml venous
blood was collected and then distributed into ethylenedi-
aminetetraacetic acid (EDTA), serum and citrate vacu-
tainer tubes, and into tubes designed for RNA preservation
(Tempus tube). Fasting glucose and cholesterol were mea-
sured by point of care tests. An oral glucose tolerance test
was carried out in a subset of participants, enabling valida-
tion of diabetes classification. A spot urine sample (6 ml in
three aliquots) was also collected for analysis of albumin-
uria and other biomarkers. Aliquots of whole blood, buffy
coat, serum, EDTA plasma, citrate plasma and urine
(Supplementary Table S3, available as Supplementary data
at IJE online) were stored at 80C for future molecular
epidemiological research (including genomics), to investi-
gate the mechanisms underpinning the development of
T2DM, CVD and other complex diseases that are of im-
portance to South Asians (including but not limited to:
obesity, cancer, dementia, chronic obstructive pulmonary
disease, chronic kidney disease).
Physical activity
This was also objectively quantified in 100-Hz resolution
using a wrist-worn triaxial accelerometer, worn on partici-
pants’ non-dominant wrist for 7 days. This device is small,
light-weight, wrist-watch-shaped, battery-powered and
uses triaxial acceleration in gravitational units to infer par-
ticipant movement. It has been used recently to measure
physical activity patterns amongst 100 000 people in the
UK Biobank study.13














Age <0.001 <0.001 <0.001 <0.001
<30 years 30.28 15.71 28.53 13.07 34.32 15.74 21.17 10.56
30-50 years 45.24 50.61 42.93 47.95 41.66 51.56 40.89 39.17
50-70 years 19.08 29.25 23.09 33.37 19.04 30.88 29.98 40.74
70 years 5.40 4.44 5.45 5.62 4.98 1.82 7.96 9.53
Sex <0.001 <0.001 <0.001 <0.001
Male 50.45 55.43 51.57 61.53 51.11 67.09 47.18 69.07
Female 49.55 44.57 48.43 38.47 48.89 32.91 52.82 30.93
Data are in percentages. The age category of ‘<30 years’ refers to ‘20–29 years’ in the United Nations Population Division and ‘18–29 years’ in SAB; chi- square
goodness of fit testing was used to determine whether the age and sex proportions in SAB were similar to those in the general population.
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Dietary intake
Consumption was recorded by interviewer-administered
computerized 24-h dietary recall based on the multiple
pass method using the Intake24 system [https://intake24.
org/]. The system was specifically adapted for the South
Asian context through incorporating extensive additional
foods, drinks and dishes, and portion-size photographs rel-
evant to the study settings. Adaptation was informed by re-
search nutritionists and dieticians from each study centre
and by the results of previous dietary surveys in the study
locations. The implementation of this tool could enable the
description of food and nutrient intakes, evaluation of
intakes in comparison with guidelines and investigation of
the link between diet and health endpoints.
All study participants received a report summarizing the
clinically relevant results of their health assessment, to-
gether with an explanatory booklet and a link to access an
explanatory video. Participants identified with significant
health conditions (e.g. T2DM, hypertension) had the op-
portunity to discuss the results with the study team, and to
be referred to an appropriate health care facility for further
assessment, counselling or treatment.
Environmental mapping
In each surveillance site, an environmental mapping exercise
was carried out. The aim was to characterize the built envi-
ronment in terms of retailers and advertisements for food and
tobacco and physical activity facilities. The methodologies
were adapted from food modules conducted by: the
International Network for Food and Obesity/NCDs Research,
Monitoring and Action Support; the Maryland Food Systems
Map conducted by the Johns Hopkins Center for a Livable
Future; and the World Health Organization Framework
Convention on Tobacco Control.14–16 In addition to geoloca-
tions, the main variables included food (e.g. fruit, vegetables,
confectionery), drinks (e.g. soft drinks, sugar-free drinks) and
tobacco products (e.g. cigarette, beedi) being sold or adver-
tised. Data collection used KoboToolBox for Android [https://
www.kobotoolbox.org] and covered each surveillance site
with a 500-m buffer beyond the site boundary.
Identification of outcomes
The primary outcomes were T2DM and cardiovascular
disease. The secondary endpoints included respiratory and
chronic kidney diseases, or cancer.
Quality control and data management
The surveillance teams, comprising research assistants, lab-
oratory technicians, physicians and coordinators, were
trained to follow standardized protocols (Supplementary
Table S4, available as Supplementary data at IJE online)
Their training modules included interviewing techniques,
ethics and specific instructions for data variables (demo-
graphic, socioeconomic, food security, behavioural risk
factors, medication and lifestyle practices, physical mea-
surement and collection of biological samples).
Revalidation of the research teams in study procedures
was done at regular intervals during the study to ensure
high-quality data collection that was harmonized across
surveillance sites. Standardized operating procedures
were established for all data collection procedures.
Questionnaires were translated into the local languages lo-
cal to the communities, and back-translated. Equipment
used for physical and biological measurements is listed in
Supplementary Table S5, available as Supplementary data
at IJE online, and was regularly calibrated using appropri-
ate controls/standards.
The data management teams reviewed the data col-
lected routinely for completeness and data quality, includ-
ing using custom computer scripts to assess for biases in
data entry, logical inconsistencies, internal correlations,
digit preference and measurement drift or bias between
machines and observers. Quality control reports were cir-
culated at weekly intervals between the study investigators,
to drive continuous evaluation and improvement in study
processes. A random subset comprising up to 2% of the
study participants, and/or a subset of biological samples,
was reassessed to provide additional quality control infor-
mation. Data collection methods used were ‘field-friendly’,
culturally acceptable and minimally invasive in order to re-
duce participant attrition and improve logistical feasibility.
Personal and clinical data were separated by pseudo-
nymization to enhance data security. All data were
encrypted during transmission and stored securely both lo-
cally and in a cloud-based infrastructure. Data and all rele-
vant documents will be stored for a minimum of 10 years.
Samples collected were split and stored in both South Asia
and the UK to ensure long-term (>20 years) sample integ-
rity and preservation. Some laboratory assays on stored
samples were done in South Asia and the majority of assays
were carried out in the UK or other countries with relevant
technologies in the future.
Data resource use
Data collected in this cross-sectional investigation could be
used to assess the epidemiology of T2DM, CVD and other
chronic diseases in South Asia. The exploration of possible
risk factors for T2DM and CVD could provide a scientific
basis for evidence-based public health policy making and
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interventions. Upon request, the rich resources of SAB are
available to researchers from all over the world.
Based on the definition of obesity by WHO, the preva-
lence of obesity (body mass index 30 kg/m2) is 6.6% in
Bangladesh, 19.7% in India, 33.9% in Pakistan and
15.7% in Sri Lanka. Similarly the prevalence of diabetes,
defined as a fasting glucose level >126 mg/dL or a physi-
cian diagnosis or current antidiabetic medication, is
11.5%, 27.7%, 25.3% and 24.8%, respectively; and the
prevalence of hypertension, defined as a systolic blood
pressure  140 mmHg or a diastolic blood pressure
 90 mmHg or a physician diagnosis or current antihyper-
tensive medication, is 26.7%, 36.9%, 44.5%, 35.0% in
Bangladesh, India, Pakistan and Sri Lanka, respectively.
Strengths and weaknesses
SAB is designed to identify the risk factors and their com-
plex interactions underlying the development of T2DM,
CVD and other chronic diseases in South Asians. With in-
tensive data collection, SAB provides representative popu-
lation samples in four South Asian countries. SAB is the
first comprehensive biobank of South Asian individuals. Its
large sample size, broad geographical reach and wide range
of data collected, including biosamples, make SAB a pow-
erful tool for epidemiological and translational research in
South Asian populations. The standardized procedures and
rigorous quality control of data collection ensure compara-
bility of study results between and within the partner coun-
tries. Further, although random sampling approaches were
used in selecting participants, we cannot exclude ‘healthy
volunteer’ effects, a common phenomenon in epidemiolog-
ical research. In addition, advanced phenotyping by imag-
ing (e.g. MRI, DXA or ultrasound) was not feasible across
the range of sites studied.
Data resource access
Reports and major results of SAB will be released regularly
on the SAB website [https://www.ghru-southasia.org/].
Any enquiries regarding SAB should be directed to
Professor John C Chambers [john.chambers@imperial.
ac.uk]. Subject to data privacy requirements and the per-
missions included in the consent form, individual-level
data and samples are available for use to approved
investigators.
Supplementary data
Supplementary data are available at IJE online.
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